

Agilex Biolabs expands to accommodate biotech and CRO demand

13 March 2020 | News

Offers virtual lab tour to the interested customers who have travel restrictions amidst COVID-19

Award-winning Australian bioanalytical laboratory Agilex Biolabs announced on 13 March 2020 it has expanded its lab facilities by more than 30% to accommodate demand, mainly from the US and APAC-based biotech companies.

Agilex Biolabs, the only FDA-inspected lab of its type in the region, is located in Adelaide, South Australia in a science and biotech specialist hub.

Agilex Biolabs CEO Jason Valentine said they will now be offering virtual lab tours to show customers who have travel restrictions during the current Covid-19 outbreak.

The company specialises in bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS and Immunoassay (MesoScale, Gyrolab).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:

- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine/biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)

CEO Jason Valentine said: "Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma/biotechs from US, Europe and

APAC.”

“By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.”

“Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition.”